1 e exacerbations of COPD as add-on therapy to standard drugs.

2 ating and NR Mtb, including Mtb resistant to standard drugs.

3 ses, and tumor blood vessels compared with a standard drug and with control and thus demonstrated pot

4 xploited as an adjunct therapy together with standard drug-based approaches.

5 urvived; it was also more effective than the standard drug benznidazole.

6 ergo allo HSCT before resistance develops to standard drug combinations.

7 hAChEIs (IC50 up to 3 nM), outperforming the standard drug donepezil (IC50 = 11 nM), most of the corr

8 drop of intraocular pressure compared to the standard drug dorzolamide.

9  progress has been made, notably in terms of standard drug dose intensification and safer allogeneic

10 steatosis when compared to the effect of the standard drug fenofibrate.

11 Here, we show that low doses of metformin, a standard drug for diabetes, inhibits cellular transforma

12 BAA receptor-positive modulator, is the gold-standard drug for treating insomnia.

13  to 53.12, which is improved compared to the standard drug Miltefosine (IC(50) 12.4 muM and SI 4.1).

14  MDR or XDR tuberculosis in combination with standard drug regimens.

15 ant tuberculosis (MDR-TB) in comparison with standard drug susceptibility testing (DST) and compared

16 opriate for patients who do not do well with standard drug therapy or for those who prefer a disease-

17 ial of aerosol IFN-gamma in conjunction with standard drug therapy, we have observed activation of IF

18                                              Standard drug treatment for OH is effective but worsens

19 is clinically better than carbamazepine, the standard drug treatment, for time to treatment failure o